Oncotelic Therapeutics, Inc. Announces Open Access to Proprietary Platform and TGF-β Corpus

On December 22, 2025, Oncotelic Therapeutics, Inc. announced the launch of PDAOAI, its proprietary platform designed to analyze large biomedical datasets without requiring custom large language models. The company is also granting researchers access to a comprehensive TGF-β literature corpus, exceeding 125,000 PubMed abstracts, via a dedicated Discord channel. This initiative aims to facilitate biological signal extraction from complex data and support research in the TGF-β field. The company has included forward-looking statements regarding its future operations, clinical development, product candidates, and potential token launches, while also noting that actual results may differ due to various risks. This information is furnished as part of a Form 8-K filing and is not deemed officially filed.